Literature DB >> 8914034

Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism.

O S Indridason1, H Heath, S Khosla, D A Yohay, L D Quarles.   

Abstract

To determine the relative importance of parathyroid gland enlargement and alterations in calcium sensing (set-point changes) in the pathogenesis of uremic secondary hyperparathyroidism (2 degrees HPT), we investigated the relationship between estimates of parathyroid gland size and calcium-mediated parathyroid hormone (PTH) suppression in 19 normocalcemic 2 degrees HPT patients on chronic maintenance hemodialysis. We compared our results to calcium-mediated PTH suppression in 12 normal volunteers, 12 patients with familial benign hypocalciuric hypercalcemia (FBHH), a disorder of abnormal calcium sensing, and 9 subjects with primary hyperparathyroidism (1 degree HPT), which is characterized by both calcium set-point abnormalities and parathyroid gland enlargement. We found that the 2 degrees HPT group displayed a distinctive pattern of calcium-mediated PTH suppression characterized by a failure to normally suppress PTH at supraphysiologic ionized calcium concentrations, similar to 1 degree HPT, but without the rightward shift of the calcium-PTH suppression curve that characterizes calcium sensing abnormalities in FBHH and 1 degree HPT. In the patients with 2 degrees HPT, hypercalcemic suppression resulted in an ending PTH (as a percent of baseline) that was significantly higher (39.8 +/- 4.47%), and a slope of the calcium-PTH suppression curve that was significantly less negative (-4.8 +/- 0.53), compared to respective values of 19.4 +/- 1.81% (P = 0.0009) and -9.0 +/- 1.02 (P = 0.001) in normals and 19.1 +/- 2.49% (P = 0.001) and -9.6 +/- 1.11 (P = 0.0006) in FBHH. Values of ending PTH and slope in 2 degrees HPT patients, however, were similar to those found in 1 degree HPT (49.8 +/- 6.35%, P = 0.21 and -4.5 +/- 0.74, P = 0.72). The ionized calcium concentration required to attain half maximal PTH suppression (EC50) in 2 degrees HPT (1.20 +/- 0.02 mmol/liter) was not significantly different from normals (1.25 +/- 0.01 mmol/liter, P = 0.12) but was significantly less than in 1 degree HPT (1.52 +/- 0.02 mmol/liter, P < 0.0001) and in FBHH (1.44 +/- 0.02 mmol/liter, P < 0.0001). More importantly, we found a significant linear correlation between the natural logarithm of gland size and ending PTH suppression (r = 0.71, P < 0.001) and slope of the calcium-PTH curve (r = 0.67, P = 0.002) in 2 degrees HPT. Thus, calcium non-suppressible PTH secretion in 2 degrees HPT does not represent a simple set-point error, but rather correlates with the degree of parathyroid gland enlargement.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8914034     DOI: 10.1038/ki.1996.483

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Two parathyroid adenomas in a Saudi female on hemodialysis diagnosed with tertiary hyperparathyroidism: a case report.

Authors:  Sara Ahmad Assiri; Arif Khurshid; Abdullah Thawabeh
Journal:  AME Case Rep       Date:  2021-01-25

2.  Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD.

Authors:  James B Wetmore; Peter W Santos; Jonathan D Mahnken; Ron Krebill; Rochelle Menard; Hema Gutta; L Darryl Quarles
Journal:  J Clin Endocrinol Metab       Date:  2010-10-13       Impact factor: 5.958

3.  Parathyroid-gland ultrasonography in clinical and therapeutic evaluation of renal secondary hyperparathyroidism.

Authors:  C Vulpio; M Bossola; S C Magalini; P Silvestri; G Fadda; M Ciliberti; M L D'Andrea; G Maresca
Journal:  Radiol Med       Date:  2012-10-22       Impact factor: 3.469

4.  The association of adiposity with parathyroid hormone in healthy older adults.

Authors:  Arpita Patel Pitroda; Susan S Harris; Bess Dawson-Hughes
Journal:  Endocrine       Date:  2009-08-27       Impact factor: 3.633

5.  Total Parathyroidectomy with Subcutaneous Parathyroid Forearm Autotransplantation in the Treatment of Secondary Hyperparathyroidism: A Single-Center Experience.

Authors:  Claudio Casella; Alessandro Galani; Luigi Totaro; Silvia Ministrini; Silvia Lai; Mira Dimko; Nazario Portolani
Journal:  Int J Endocrinol       Date:  2018-07-09       Impact factor: 3.257

6.  The value of clinical-ultrasonographic feature model to predict the severity of secondary hyperparathyroidism.

Authors:  Xiaoer Zhang; Wenxin Xu; Tongyi Huang; Jingzhi Huang; Chunyang Zhang; Yutong Zhang; Xiaoyan Xie; Ming Xu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

7.  Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism.

Authors:  Mario Meola; Ilaria Petrucci; Giuliano Barsotti
Journal:  Nephrol Dial Transplant       Date:  2009-01-30       Impact factor: 5.992

8.  Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.

Authors:  Sohyun Jeong; In-Wha Kim; Kook-Hwan Oh; Nayoung Han; Kwon Wook Joo; Hyo Jin Kim; Jung Mi Oh
Journal:  Drug Des Devel Ther       Date:  2016-07-08       Impact factor: 4.162

9.  Assessing the accuracy and reliability of ultrasonographic three-dimensional parathyroid volume measurement in a patient with secondary hyperparathyroidism: a comparison with the two-dimensional conventional method.

Authors:  Sung-Hye You; Sang-Il Suh; In-Seon Ryoo; Gyu-Ri Son; Young-Hen Lee; Hyung Suk Seo; Nam Joon Lee; Hae Young Seol
Journal:  Ultrasonography       Date:  2016-06-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.